Celularity Inc.

NasdaqCM:CELU Stock Report

Market Cap: US$52.2m

Celularity Management

Management criteria checks 3/4

Celularity's CEO is Bob Hariri, appointed in Jul 2021, has a tenure of 3.5 years. total yearly compensation is $1.23M, comprised of 97.2% salary and 2.8% bonuses, including company stock and options. directly owns 12.66% of the company’s shares, worth $6.61M. The average tenure of the management team and the board of directors is 3.3 years and 3 years respectively.

Key information

Bob Hariri

Chief executive officer

US$1.2m

Total compensation

CEO salary percentage97.2%
CEO tenure3.5yrs
CEO ownership12.7%
Management average tenure3.3yrs
Board average tenure3yrs

Recent management updates

Recent updates

Celularity Inc. (NASDAQ:CELU) Held Back By Insufficient Growth Even After Shares Climb 80%

Feb 14
Celularity Inc. (NASDAQ:CELU) Held Back By Insufficient Growth Even After Shares Climb 80%

Celularity appoints Adrian Kilcoyne as chief medical officer

Oct 03

Celularity falls after announcing fund raising deal

Sep 15

Celularity falls 10% on deal for $150M common stock offering

Sep 08

Celularity begins phase 1/2a trial for cell therapy CYNK-101 to treat cancers

Jul 27

CEO Compensation Analysis

How has Bob Hariri's remuneration changed compared to Celularity's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$35m

Jun 30 2024n/an/a

-US$113m

Mar 31 2024n/an/a

-US$154m

Dec 31 2023US$1mUS$1m

-US$196m

Sep 30 2023n/an/a

-US$181m

Jun 30 2023n/an/a

-US$83m

Mar 31 2023n/an/a

US$13m

Dec 31 2022US$5mUS$1m

US$14m

Sep 30 2022n/an/a

-US$14m

Jun 30 2022n/an/a

US$31m

Mar 31 2022n/an/a

-US$81m

Dec 31 2021US$22mUS$1m

-US$100m

Sep 30 2021n/an/a

-US$92m

Jun 30 2021n/an/a

-US$188m

Mar 31 2021n/an/a

-US$260m

Dec 31 2020US$3mUS$1m

-US$208m

Compensation vs Market: Bob's total compensation ($USD1.23M) is above average for companies of similar size in the US market ($USD643.82K).

Compensation vs Earnings: Bob's compensation has been consistent with company performance over the past year.

CEO

Bob Hariri (65 yo)

3.5yrs

Tenure

US$1,234,342

Compensation

Dr. Robert Joseph Hariri, also known as Bob, M.D., Ph.D. is a Co-Founder of Human Longevity, Inc. and serves as President of Human Longevity Cellular Therapeutics. He serves as Medical Advisor at Beyond Im...

Leadership Team

NamePositionTenureCompensationOwnership
Robert Hariri
Founder3.5yrsUS$1.23m12.66%
$ 6.6m
John Haines
Senior EVP2.3yrsUS$815.82k0.067%
$ 35.0k
David Beers
Chief Financial Officer3.5yrsUS$1.71m0.033%
$ 17.1k
Carlos Ramirez
SVP of Investor Relationsno datano datano data
Stephen Brigido
President of Degenerative Diseases3.5yrsno data0.0025%
$ 1.3k
Sharmila Koppisetti
Senior Vice President of Clinical Dev. Immunology & Drug Safety3yrsno datano data
Tim Wilk
Senior Vice President of Technical Operations1.6yrsno datano data
David Lemus
Treasurerno datano datano data

3.3yrs

Average Tenure

62yo

Average Age

Experienced Management: CELU's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Robert Hariri
Founder3.5yrsUS$1.23m12.66%
$ 6.6m
Richard Jay Berman
Independent Directorless than a yearno datano data
Diane Parks
Independent Director2.6yrsUS$322.50k0.10%
$ 54.8k
Louis Weiner
Member of Scientific Advisory Board3yrsno datano data
Dean Kehler
Independent Director7yrsUS$354.75k1.23%
$ 639.2k
Peter Diamandis
Independent Director3.5yrsUS$326.50k5.81%
$ 3.0m
Geoffrey Shiu Ling
Independent Director1.3yrsUS$301.25k0%
$ 0
Darren Sigal
Co-Chairman of Scientific Advisory Boardno datano datano data

3.0yrs

Average Tenure

67yo

Average Age

Experienced Board: CELU's board of directors are considered experienced (3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/23 23:20
End of Day Share Price 2025/01/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Celularity Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Thomas ShraderBTIG
Swayampakula RamakanthH.C. Wainwright & Co.